Fig. 1 · Structure

Documents & Downloads

Zandelisib

Cat. No. A12273 CAS 1401436-95-0

PI3K Inhibitor

Zandelisib is a selective, orally active, non-covalent inhibitor of PI3Kδ. It effectively inhibits AKT phosphorylation and suppresses downstream signaling pathways, making it a valuable tool in cancer research. Zandelisib is particularly relevant for studying malignancies such as relapsed or refractory B-cell lymphoma, providing insights into tumor behavior and therapeutic response.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Zandelisib Research Summary

This section summarizes 1 in vitro study of Zandelisib from 1 published reference. In vitro models include biotinylated PIK3CD/PIK3R1.

Zandelisib In Vitro Studies

Zandelisib was evaluated against biotinylated PIK3CD/PIK3R1 using a single-cycle kinetics assay with buffer injections as the control. The reported equilibrium dissociation constant for ME-401 was 30 pM. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Zandelisib Binding in a Single-Cycle Kinetics Assay

Cell-based study · biotinylated PIK3CD/PIK3R1 [1]

Zandelisib was evaluated against biotinylated PIK3CD/PIK3R1 using a single-cycle kinetics assay. The reported equilibrium dissociation constant for ME-401 was 30 pM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
equilibrium dissociation constantKD KD of 3.03 × 10−11 M[1]

Literature-Reported Treatment Conditions

Treatment concentration
1–100 nM
Exposure duration
a contact time of 100 s, and a flow rate of 30 µL/min. The dissociation period was 1200 s.
Method
Single-cycle kinetics assay
Vehicle
Biacore buffer containing 1% DMSO
Methods and source locations

Compound reported in the paper: Zandelisib; Compound label in the paper: ME-401

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > In Vitro Blood to Plasma Ratio, Permeability, and Binding Kinetics > Purified Enzyme-Binding Kinetics (S35, S42, S43, S44, S46, S52); Results > In Vitro Blood to Plasma Ratio, Permeability, and Binding Kinetics > Equilibrium Dissociation Constant (KD) and On/Off Rates (S102); Table 2 legend (S121)

equilibrium dissociation constant: equilibrium dissociation constant; comparator: buffer injections — Results > In Vitro Blood to Plasma Ratio, Permeability, and Binding Kinetics > Equilibrium Dissociation Constant (KD) and On/Off Rates (S102); Table 2 legend (S121)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1401436-95-0
Applications PI3K Inhibitor
Formula C31H38F2N8O
Molecular Weight 576.68
Synonyms ME-401; PWT-143
SMILES
CN1CCC(C2=CC=CC=C2CC(NC3=NC(N4C5=CC=CC=C5N=C4C(F)F)=NC(N6CCOCC6)=N3)(C)C)CC1

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Zandelisib Research References

  1. [1] Moreno O, Wood J. Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase δ (PI3Kδ) in Animal and B-Cell Lymphoma Models. Target Oncol (2019). PMID: 31506873 DOI: 10.1007/s11523-019-00668-y Source material

Added to your cart

View Cart Checkout
Loading...